The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 25, 2017

Filed:

Jul. 07, 2014
Applicant:

The Regents of the University of California, Oakland, CA (US);

Inventors:

David Cheresh, Encinitas, CA (US);

Laetitia Seguin, San Diego, CA (US);

Sudarshan Anand, San Diego, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01); A61K 38/05 (2006.01); B65D 75/36 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); A61K 31/454 (2006.01); A61K 33/24 (2006.01); G01N 33/50 (2006.01); A61K 31/337 (2006.01); A61K 31/437 (2006.01); A61K 31/5377 (2006.01); A61K 31/69 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/715 (2006.01); A61K 31/4985 (2006.01); A61K 31/7068 (2006.01); A61K 38/12 (2006.01); B65D 75/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5011 (2013.01); A61K 31/337 (2013.01); A61K 31/437 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/69 (2013.01); A61K 31/7068 (2013.01); A61K 31/715 (2013.01); A61K 33/24 (2013.01); A61K 38/05 (2013.01); A61K 38/12 (2013.01); A61K 45/06 (2013.01); B65D 75/002 (2013.01); B65D 75/36 (2013.01); G01N 33/5008 (2013.01); G01N 33/57492 (2013.01); G01N 33/57496 (2013.01); G01N 2333/4724 (2013.01); G01N 2333/485 (2013.01); G01N 2333/70557 (2013.01); G01N 2333/914 (2013.01); G01N 2800/52 (2013.01);
Abstract

In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell. In alternative embodiments, the invention provides compositions and methods for determining: whether an individual or a patient would benefit from or respond to administration of a Growth Factor Inhibitor, or, which individuals or patients would benefit from a combinatorial approach comprising administration of a combination of: at least one growth factor and at least one compound, composition or formulation used to practice a method of the invention, such as an NFKB inhibitor, such as a lenalidomide or a REVLIMID™, or IKK inhibitor; or an inhibitor of Galectin-3.


Find Patent Forward Citations

Loading…